Potential targets for boron transport in boron neutron capture therapy
-
By
-
Yucai Wei
-
Weijing Zhu
-
Qian Chen
-
Huda Alnufaei
-
Yumin Li
-
Kate Ricketts
-
May 28, 2026
-
Clinical Scorecard: Identifying Potential Boron Transport Mechanisms in Boron Neutron Capture Therapy
At a Glance
| Category | Detail |
|---|
| Condition | Cancer |
| Key Mechanisms | Boron Neutron Capture Therapy (BNCT) utilizes boron-10 (10B) drug administration and neutron irradiation to selectively kill cancer cells. |
| Target Population | Patients with malignant glioma, melanoma, and head and neck cancer. |
| Care Setting | Clinical settings offering BNCT. |
Key Highlights
- BNCT is effective for recurrent and diffuse tumors.
- 10B accumulation in tumors requires concentrations ≥ 20 μg/g.
- LAT1 is a primary mediator of BPA transport in tumor cells.
- Only two 10B carriers, BSH and BPA, are approved for clinical use.
- LAT1 expression correlates with tumor proliferation and prognosis.
Guideline-Based Recommendations
Diagnosis
- Assess LAT1 expression levels in tumor tissues.
Management
- Utilize BPA and BSH for BNCT based on tumor characteristics.
Monitoring & Follow-up
- Monitor 10B accumulation and distribution in tumors.
Risks
- Consider potential cytotoxicity and normal tissue accumulation of boron carriers.
Patient & Prescribing Data
Patients with specific types of cancer showing high LAT1 expression.
BPA uptake is enhanced in LAT1-overexpressing tumor cells.
Clinical Best Practices
- Evaluate the tumor/normal tissue and tumor/blood 10B concentration ratios.
- Explore the use of L-tyrosine and other substrates to enhance BPA accumulation.
Related Resources & Content
